Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GPCR
Upturn stock ratingUpturn stock rating

Structure Therapeutics Inc. American Depositary Shares (GPCR)

Upturn stock ratingUpturn stock rating
$20.74
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: GPCR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

14 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $76.32

1 Year Target Price $76.32

Analysts Price Target For last 52 week
$76.32Target price
Low$13.22
Current$20.74
high$47.48

Analysis of Past Performance

Type Stock
Historic Profit 43.8%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.21B USD
Price to earnings Ratio -
1Y Target Price 76.32
Price to earnings Ratio -
1Y Target Price 76.32
Volume (30-day avg) 14
Beta -1.97
52 Weeks Range 13.22 - 47.48
Updated Date 06/30/2025
52 Weeks Range 13.22 - 47.48
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.58

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -17.24%
Return on Equity (TTM) -22.85%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 383579682
Price to Sales(TTM) -
Enterprise Value 383579682
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -13.46
Shares Outstanding 57536800
Shares Floating 146219869
Shares Outstanding 57536800
Shares Floating 146219869
Percent Insiders 2.74
Percent Institutions 101.14

Analyst Ratings

Rating 4
Target Price 76.32
Buy 6
Strong Buy 8
Buy 6
Strong Buy 8
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Structure Therapeutics Inc. American Depositary Shares

stock logo

Company Overview

overview logo History and Background

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapeutics for chronic diseases with significant unmet needs. Founded in 2016, the company leverages its structure-based drug discovery platform to design and develop differentiated product candidates targeting validated G protein-coupled receptors (GPCRs).

business area logo Core Business Areas

  • GPCR-Targeted Drug Discovery: Focuses on developing oral small molecule therapeutics that selectively target GPCRs to treat a range of chronic diseases, primarily in metabolic and pulmonary indications.

leadership logo Leadership and Structure

Raymond Stevens is the Founder, CEO, and Board Director. The company has a leadership team with experience in drug discovery, development, and commercialization. Structure is organized into research, development, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • GSBR-1290 (Oral GLP-1R Agonist): An oral small molecule GLP-1 receptor (GLP-1R) agonist being developed for the treatment of type 2 diabetes and obesity. Currently in Phase 2 clinical trials. Market share is currently 0 due to developmental stage. Competitors include Novo Nordisk (Semaglutide), Eli Lilly (Tirzepatide) in injectable form and Pfizer and others developing oral GLP-1 therapies.
  • ANPA-0073 (Oral Apelin Receptor Agonist): An oral Apelin receptor (APJR) agonist in development for idiopathic pulmonary fibrosis (IPF). Currently in Phase 1 trials. Market share is currently 0 due to developmental stage. Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb are competitors in IPF.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive, with companies focusing on developing innovative therapies for various diseases. The metabolic and pulmonary disease areas are experiencing significant growth due to the rising prevalence of diabetes, obesity, and pulmonary diseases.

Positioning

Structure Therapeutics aims to differentiate itself through its structure-based drug discovery platform, focusing on oral small molecule therapeutics targeting GPCRs. This approach aims to provide convenient and effective treatment options compared to injectable therapies.

Total Addressable Market (TAM)

The combined TAM for diabetes, obesity, and IPF is estimated to be over $100 billion. Structure Therapeutics is positioning itself to capture a portion of this market with its oral therapeutics targeting these indications.

Upturn SWOT Analysis

Strengths

  • Proprietary Structure-Based Drug Discovery Platform
  • Experienced Management Team
  • Strong Pipeline of Oral GPCR-Targeted Therapeutics
  • Focus on High Unmet Needs

Weaknesses

  • Clinical Stage Company with No Approved Products
  • Dependence on Successful Clinical Trial Outcomes
  • High Cash Burn Rate Associated with Drug Development
  • Limited Commercialization Experience

Opportunities

  • Potential to Disrupt Injectable Therapy Markets with Oral Alternatives
  • Expansion of Pipeline into Additional GPCR Targets
  • Strategic Partnerships and Collaborations
  • Positive Clinical Trial Results Driving Market Value

Threats

  • Clinical Trial Failures
  • Competition from Established Pharmaceutical Companies
  • Regulatory Hurdles and Delays
  • Patent Expiration and Generics

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • LLY
  • PFE
  • VRTX

Competitive Landscape

Structure Therapeutics is a clinical-stage biopharmaceutical company and currently has no drugs on the market. Competitors are much larger and already have multiple drugs on the market.

Growth Trajectory and Initiatives

Historical Growth: Structure Therapeutics's growth has been primarily driven by pipeline advancement and increased R&D spending.

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates project significant revenue growth upon commercialization of GSBR-1290 and other pipeline assets.

Recent Initiatives: Recent initiatives include advancing GSBR-1290 into Phase 2b clinical trials, initiating Phase 1 trials for ANPA-0073, and expanding the drug discovery platform.

Summary

Structure Therapeutics is a clinical-stage biopharmaceutical company with a promising structure-based drug discovery platform. The company's lead asset, GSBR-1290, has the potential to disrupt the diabetes and obesity market. However, the company faces risks associated with clinical trial outcomes and competition from established pharmaceutical companies. Successful clinical trials and strategic partnerships are crucial for the company's future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Structure Therapeutics Inc. American Depositary Shares

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2023-02-03
CEO & Director Dr. Raymond C. Stevens Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 183
Full time employees 183

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.